Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2019-08-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding a change in accounting policies. It references a specific regulatory notice (财会〔2019〕6号) issued by the Ministry of Finance that requires changes in the format of financial statements starting from the 2019 interim and annual reports. The document details the nature of the accounting policy changes, their impact on financial statement line items, and the board's rationale for the change. It is a formal announcement of a policy change rather than a full financial report or audit report. The document length is relatively short (2302 characters), and it does not contain actual financial statements or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for announcements that do not fit other specific categories and are not full reports themselves.
2019-08-26 Chinese
关于转让子公司部分应收账款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Haier Bioengineering Co., Ltd. regarding the transfer of part of its subsidiary's accounts receivable. It details the transaction's purpose, authorization, and impact on the company. There is no financial statement or detailed financial report included, nor is it a transcript, audit report, or management discussion. The document is a formal announcement of a capital transaction related to asset management and financing activities. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. The content aligns best with a Capital/Financing Update (CAP) as it concerns the transfer of receivables to improve liquidity and cash flow. The document length is short and focused on the transaction announcement, not a full report or presentation.
2019-08-26 Chinese
2019年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司 2019 年半年度财务报告" which translates to "Shenzhen Haier Bioengineering Co., Ltd. 2019 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. The report explicitly states it is a half-year (semi-annual) financial report for the period ending June 30, 2019. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. The presence of comprehensive financial data and analysis confirms it is an Interim / Quarterly Report rather than just an earnings release or announcement. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2019
2019-08-26 Chinese
第七届监事会第二十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding the approval of the company's 2019 semi-annual report and its summary. It confirms the report's compliance with legal and regulatory requirements and states the meeting details and voting results. The document itself does not contain the semi-annual report or detailed financial data but is an announcement of the Supervisory Board's approval of that report. Given the short length (723 characters) and the nature of the content, this fits the category of a Regulatory Filing (RNS) rather than the actual Interim/Quarterly Report (IR).
2019-08-26 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2019 年半年度报告摘要' which translates to '2019 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, cash flow, and financial ratios for the half-year period. It also includes management discussion and analysis of business segments, changes in accounting policies, and other operational details. The length is over 6,000 characters and it contains substantive financial data and analysis, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-26 Chinese
关于2017年度第一期中期票据2019年付息完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of interest payment for a medium-term note issued by the company. It details the issuance, registration, and payment of interest on debt financing instruments. The content focuses on financing activities, specifically the payment of interest on bonds, which aligns with updates on company fundraising and capital structure changes. The document is relatively short (971 characters) and is not a full financial report but an update on financing activity. Therefore, it fits best under the category 'Capital/Financing Update' (CAP).
2019-08-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.